Novel Targets and Pathways

• 3040 · PDF FOXM1 as a drug target in NF1-associated malignant peripheral nerve sheath tumors Ellen M. Voigt, Quinn Hanigan, Joshua J. Lingo, Altay Koyas, Rebecca D. Dodd, Benjamin W. Darbro, Dragana Kopanja, Sung Hoon Kim, Benita S. Katzenellenbogen, John A. Katzenellenbogen, Dawn E. Quelle
• 3041 · PDF Selective PARP2 inhibitor disrupting PARP2-FOXA1 interaction to inhibit androgen receptor signaling in prostate cancer Fu Gui, Wenfei Hu, Qi Miao, Zhi Tan, Mingxing Teng, Adam S. Kibel, Wei Zhang, Li Jia
• 3042 · PDF Inhibition of d e novo purine biosynthesis via PPAT targeting by cucurbitacin B restrains esophageal squamous cell carcinoma growth Mengqiu Song, Jing Guo, Huajie Jia, Jie Tian, Pan Li, Zigang Dong
• 3043 · PDF CKAP2 modulation with a novel small molecule results in excellent in-vitro and in-vivo anti tumor activity Deepa M. Sridharan, Vignesh Viswanathan, Dmitry Kuchenov, Quynh Mai, Yerem Yeghiazarians, Kurosh Ameri
• 3044 · PDF PKMYT1 inhibition is synthetically lethal with CCNE1 overexpression and synergizes with standard of care chemotherapy Natalie Hill, Jeremy Fournier, Srijita Bhowmik, Jenny Zhu, Saranya Chandrasekar, Ester Fernandez-Salas, Samantha S. Hodge
• 3045 · PDF TM4SF20 scaffolds DDR1-IRS4 signaling to drive PDAC metastasis and represents a druggable therapeutic target Xinyue Liu, Weishuai Liu, Antao Chang, Jihui Hao
• 3046 · PDF Robust and durable antitumor activity of a novel PDE10 inhibitor, ADT-030, that enhances the efficacy of chemotherapy and immunotherapy by blocking RAS and beta-catenin signaling and overcoming resistance to RAS-selective inhibitors Gary A. Piazza, Dhana Sekhar Reddy Bandi, Veronica Ramirez Alcantara, Ganji Purnachandra Nagaraju, Junwei Wang, Sindhu Ramesh, Kristy Berry, Khalda Fadlalla, Elmar Nurmemmedov, Ivan Babic, Md Yeashin Gazi, Xi Chen, Jeremy B Foote, Adam B Keeton, Yulia Y. Maxuitenko, Donald Buchsbaum, Fokhrul Hossain, Gang Zhou, Bassel F. El-Rayes
• 3047 · PDF A small molecule inhibitor of NVL suppresses tumor growth by blocking ribosome biogenesis Arin B. Aurora, Holly H. Guo, Ye Tao, Victor E. Cruz, Min Fang, VIshal Khivansara, Shanhai Xie, Ashley Leach, Divya Reddy, Johann Peterson, Jiwoong Kim, Noelle S. Williams, Jan P. Erzberger, Jef K. De Brabander, Deepak Nijhawan
• 3048 · PDF Nesuparib enhances anti-tumor efficacy with gemcitabine and nab-paclitaxel in BRCA wild type pancreatic cancer xenograft model Banyoon Cheon, Jung-young Shin, Geon Kang, Dae In Park, John Kim, Hyunju Cha
• 3049 · PDF Atamparib: First-in-class PARP7 inhibitor for treatment of NSCLC adenocarcinoma in monotherapy and in combination with standards of care Genny Degani, Federica Carbone, Patrizia Banfi, Laura Gianellini, Nilla Avanzi, Elena Casale, Marina Fasolini, Laura Riva, Gianluca Papeo, Francesca Quartieri, Fabio Gasparri, Michael O. Hottiger, Claudia Perrera, Alessia Montagnoli
• 3050 · PDF RPT1G, a novel hyperbolic NAMPT inhibitor, effectively synergizes with PARP inhibitors in solid tumors in vitro and in a xenograft breast cancer model Michael Schelle, Min Wu, Francis Roushar, Banumathi Cole, Dennise A. De Jesús-Díaz, Gregory Thomas Crimmins
• 3051 · PDF Enhancing matchmaking in targeted therapy (TT) for cancer (ca): Beyond the ‘arranged' criteria Farah Mazahreh, Liyan Mazahreh, Ahmad Mazin Safar
• 3052 · PDF RK-582, a tankyrase inhibitor, attacks Wnt-driven colorectal cancer cells with short-type APC mutations and high beta-catenin expression Hiroyuki Seimiya, Mingjue Chen, Taichi Oishi, Yukiko Muramatsu, Manabu Takamatsu, Naomi Kawata, Ayane Nakamura, Saori Inaba, Satoshi Nagayama, Ryohei Katayama, Kensei Yamaguchi, Fumiyuki Shirai, Tetsuo Mashima
• 3053 · PDF Combination of the MDM2 antagonist ASTX295 and Olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors Antonio Morales, Joanna Obacz, Bryn Hardwick, Adam Jackson, Liam Davis, Zoe Haines, Patrick Herr, Paula Martinez Sanz, Violetta Serra, Judit Espana-Agusti, Gianni Chessari, Maria Ahn, John F. Lyons, Amy Emery, Sarah Holt, Stephen Shuttleworth, Barry R. Davies
• 3054 · PDF Inhibition of ARNT suppresses growth of primary human kidney cancer cells Shengchen Su, Yanping Wang, Yanchun Zhang, Patrick Tamukong, Hyung L. Kim
• 3055 · PDF Targeting the MKK3/MYC protein-protein interaction to overcome drug resistance in MYC-driven cancers Payton Fleming, Elsa Bildtsen, Zhen Chen, Eric J. Miller, Yuhong Du, Shi-Yong Sun, Haian Fu, Andrey A. Ivanov
• 3056 · PDF Inhibition of oncogenic phenotypes by hexanoate in triple-negative breast cancer Nahara Yupe-Muñiz, Samira B.F. Abdullah-Vargas, Oscar A. Loperena-González, Ariana S. García- López, Gabriel Borges-Vélez, Josué Pérez-Santiago
• 3058 · PDF A first-in-class orally bioavailable small molecule tumor suppressor activator for the treatment of a wide range of cancers Hee-Sung Park, Chakrapani Subramanyam, Kyu-kwang Cho, Se Hee Hyun, Yeonjee Kahm
• 3059 · PDF Targeting metabolic dependencies in MYC-driven osteosarcoma through Lp-PLA2 inhibition Katherine Shelmidine, Juan Dou, Tajhal Patel, Jason Yustein
• 3060 · PDF Periplocin restores HTR1E signaling by CTCF to inhibit proliferation and dissemination of ovarian cancer Rong Xiang, Haojie Chen, Yi Shi, Huimin Liu, Kejia Xu
• 3061 · PDF CS231295, a novel AURKB-biased multi-kinase inhibitor, demonstrates synthetic lethality in RB1-deficient tumors and potent intracranial efficacy You Zhou, Qianjiao Yang, Qinyi Xia, Yu Zhang, Zhijian Li, Desi Pan, Song Shan
• 3062 · PDF TRIM7 inhibition blocks RTK/RAS pathway driven tumor proliferation independent of mutation and in the setting of KRASi resistance Yuhui Chen, Marc Morra, Haru Kato, Kevin Li, Ulhas Bhatt, Kevin Gayler, Grace Elliott-Fromm, Nathan Oien, Julio Medina, Taylor H. Schreiber, George Fromm
• 3063 · PDF Selective cytotoxicity of butyrate highlights its potential as a targeted anti-cancer agent Nahara Yupe-Muñiz, Josué Pérez-Santiago, Gabriel Borges-Vélez, Esther A. Peterson-Peguero, Ariana García-Lopez, Amanda Prats-Marrero, Samira B.F. Abdullah-Vargas
• 3064 · PDF Synergistic combinations of novel small molecule CtBP inhibitors with DR5 agonists or BH3-mimetic PROTACs targeting chemoresistant high grade serous ovarian carcinoma Kranthi Kumar Chougoni, Nicholette St. Martin, Diana T. Dcona, Nari Kim, Boxiao Ding, Ronny I. Drapkin, Keith C. Ellis, Steven R. Grossman
• 3065 · PDF Therapeutic efficacy of CK2 inhibitor in patient-derived lung metastatic model of Ewing sarcoma Muhammad Danial, Chandrika Gowda, Rajesh Rajaiah, Marudhu Pandiyan Shanmugam, Upendar Golla, Sholler Chloe, Jeremey Hengst, Abhinav Beeravally Nagulapally, Yasin Uzun, Hannah Valensi, Matthew Lanza, Giselle L. Saulnier Sholler
• 3066 · PDF A novel class of allosteric CDK8/19 inhibitors induces synthetic lethality through concurrent mTOR and c-MYC suppression and activation of p53-mediated G2/M arrest Hui Chen, Zihan Xu, Erpei Wang, Jason Rivera, Judith Varner
• 3067 · PDF Short-chain fatty acids suppress invasion and clonogenic survival in triple-negative breast cancer cells Amanda Prats-Marrero, Ariana S. García-López, Liah M. Román-Calderón, Samira B. F. Abdullah-Vargas, Gabriel Borges-Vélez, Esther Peterson-Peguero, Josué Pérez-Santiago
• 3068 · PDF Targeting ornithine aminotransferase as a promising therapeutic strategy for hepatocellular carcinoma Wenan Qiang, Yi Yang, Tommy Ouyang, Vivian Chen, Alice Qiu, Richard B. Silverman
• 3069 · PDF Involvement of ROS species in amiloride derivative-induced lysosome-dependent cell death in triple-negative breast cancer cells Noemi Castro, Michelle Hu, Anastasia Berg, Ruiwu Liu, KIT LAM, Kermit Carraway III

在完整检索应用中浏览本分会场 →